p ulmonary alveolar proteinosis (PAP) is a rare lung disease where periodic acid SchitYs reaction (PAS)-posirive material is progressively accumulated in the alveolar space (1) . The intraalveolar material is pulmonary surfactant, a mixture of surfactant proteins (SP-A, B, C, and D) and phospholipids (2) . Human PAP is classified into three categories: adult, infantile, and congenital forms. The infantile and congenital forms lead to early respiratory failure, and the prognosis is poor (3) . Adult type is not as severe, but can be complicated by opportunistic infection (1) .
Gene knockout techniques have provided a number of mouse models that are similar to human diseases. One example is the PAP-like disease in mice that harbor targeted mutation in the GM-CSF ligand (4, 5) or the [3c receptor gene (receptor for GM-CSF, IL-3, and IL-5) (6, 6a) . The lungs of the ~c receptor mutant mice show a progressive accumulation of PAS-positive proteinaceous substance in the alveolar spaces, as well as peribronchovascular lymphocyte infiltration.
The morphology of alveolar macrophages in the lungs of the mutant mice is grossly abnormal. These macrophages are expanded by cytosolic ingested material and appear distended and foamy. It is therefore possible that GM-CSF produced in the lung may be a necessary signal through the [3c receptor for the appropriate degradation of suffactant internalized in alveolar macrophages. Alternatively, as type II pneumocytes are also involved in surfactant production and resorption (7) , a nonhematopoietic basis to the disease is also possible.
If alveolar macrophages are a primary cause of the lung disease in [3c receptor mutant mice because of a cell-autonomous defect, it should be possible to manipulate the lung disease by bone marrow transplantation. It has been shown that alveolar macrophages are derived from bone marrow precursors in rodent systems (8, 9) , and also in humans (10) . Although steady-state hematopoiesis of [3c mutant mice appeared normal, except for reduced levels of eosinophils (6), we sought to explore the relationship between the lung disease and the hematopoietic system by bone marrow transplantation studies. The data presented define that [3c-deficient PAP is hematopoietic in nature, and is likely to involve alveolar macrophages.
Materials and Methods
Mice. All animals used in this study were raised and housed in microisolator cages at the DNAX Research Institute animal facility. The production of the Bc mutant animals has been described previously (6) . These animals have routinely tested negative for typical mouse pathogens. Wild-type (WT) and [3c mutant donor and recipient animals were derived from littermate-matched offspring and represent an F 3 generation of 129 • C57B1/6 background. In other identical experiments, the WT animals used as bone marrow donors were of an F1 (129 • C57B1/SJL) genetic backgound. These WT F~ donor cells were haplocongenic at the Ly 5 locus (Ly 5.1 and Ly 5.2), due to the C57B1/SJL congenic parent, allowing marking of the donor versus recipient cell populations (11) . Recombination Activating Gene-2 (RAG-2) mutant animals used for donor cells were of 129 genetic background. 129, C57B1/6, and C57/SJL are matched for H-2 b.
Bone Marrow Transplantation. Recipient mace were irradiated by two doses of 600 rad, 12-16 h apart, from a 137Cs source. After irradiation, animals were injected intravenously with 106 bone marrow cells. Marrow cells were flushed out of the femur and depleted of RBCs by osmotic shock. All recipient animals were 2-3-mo old at the time of transfer except for the recipients in R.ag-2 transfer experiment where animals were 7-too old. All donor animals were 2-3-mo old.
Lung Pathologic Evaluation. Lung sections were prepared for pathology and stained with either hematoxylin and eosin or with PAS as previously described (6) . After transplantation at the indicated time periods, random step sections from each mouse (minimum of three) were prepared and placed into a histopathological category.
Cell Preparation from Bronchoalveolar Lavage, Immunohistochemistry, and Protein Determination. Animals were killed and lungs were washed with PBS three times by inserting thin tubing attached to a syringe into the trachea. Centrifuged bronchoalveolar lavage (BAL) cells were cytospun and stained with Wright-Giemsa. For immunohistochemistry, lung tissue was fixed with 4% paraformaldehyde in PBS overnight at 4~ embedded into OCT compound, and cut into 6-p,m-thick sections. After blocking endogenous biotin and peroxidase, the samples were treated with 5% mouse serum for 30 rain at room temperature, stained with biotinylated anti-Ly 5.2 antibody for 1 h at room temperature, developed using a LSAB kit (DAKO, Glostrup, Denmark), then counterstained with hematoxylin.
For determination of protein in the BAL fluid, the lungs were washed three times with a total volume of 3 ml PBS. BAL fluid was centrifuged to remove cells and the total protein concentration was determined using a BCA protein assay kit (Pierce, Rockford, IL). 
Peripheral Blood Staining.

Results and Discussion
Bone Marrow Transplantation. To address the potential link between hematopoiesis and the lung pathology in [3c mutant mice, bone marrow from WT animals was transferred into lethally irradiated [3c mutant recipient animals in an attempt to cure the PAP. Mice were evaluated at 8 and 12 wk after bone marrow transplantation.
In control experiments, transfer of WT donor cells into
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WT recipient animals resulted in lung physiology similar to that of unmanipulated WT animals ( Fig. 1 a) . Transfer of J3c mutant bone marrow to [3c mutant recipient animals resulted in the typical PAP pathology of discreet intraalveolar material in the alveolar spaces ( Fig. 1 b) . However, transfer of WT bone marrow into [3c mutant recipient mice resuited in a striking improvement in the lung pathology at 8 and 12 wk after transfer ( Fig. 1 c) . The intraalveolar substance defining PAP was completely absent or only residual, and in clear contrast to the pathology observed in J3c mutant animals that received [3c mutant bone marrow (compare Fig. 1 b to c) . To quantitate the reversal of PAP, we performed multiple step sections of the lungs of each of the animals in the three transplanted groups described above. A pathological evaluation of each of these tissue sections was done by placing each specimen into a histopathologic category of 1 (normal lung)-5 (severe lung pathology).
(The characteristics of each category are described in the legend to Fig. 2 .) Fig. 2 shows that the WT animals that had received WT bone marrow were classified as category 1 or 2.
[3c mutant animals that had received [3c mutant bone marrow were classified as category 4 or 5.
[3c mutant animals that received WT donor bone marrow were classified as categories 2 or 3 at 8 wk after transplant and as category 3 at 12 wk after transplant. 100% of the [3c mutant animals that received WT bone marrow completely cleared the intraalveolar material, the defining characteristic of PAP. However, as the 13c mutant animals were undergoing the disease state before transplant, residual damage to the lung tissue was detected after clearance of the disease state, as described below. The histopathologic category of the lung specimens from animals cured of PAP (WT to J3c mutant transplanted group) was not identical to the animals of the WT to WT transplanted group. The types of changes accounting for this difference were independent of the characteristics of PAP and consisted of two general findings. Areas of focal alveolar macrophage accumulation (and possibly type II pneumocytes) were detected. The arrows in Fig. 1 c show this cellular accumulation visualized by hematoxylin and eosin staining, and the arrows in Fig. 1 d show that the focal accumulation of cells contain PAS-positive material. Other changes in the lung where the disease was reversed included occasional areas of collapsed alveolar septa and a limited amount of fibrosis (data not shown). Collectively, the changes in the lung that distinguish WT to [3c mutant transplanted groups from WT to WT transplanted groups are distinct from the progressive pathology of PAP, and may be indicative of reparative processes that accompany the reversal of PAP, as well as the remains of direct damage caused to the lung tissue during the disease state.
Protein Accumulation Was Reversed in WT to tic Mutant
Transplanted Animals. To independently veil@ that the disease was reversed, a group of WT to [3c mutant animals was killed 10 wk after transplant, and total protein from BAL fluid was determined. (Fig. 3, control panels) . After W T to [3c mutant animal transplantation, recipient animals contained predominant, but not absolute, donor cell phenotypes in the peripheral blood (Fig. 3 , BMT WT-+[3c KO). The distribution o f W T F 1 donor cells in the lung was followed by immunohistochemistry of lung sections using the antibody against Ly5.2. Significant numbers of W T Ly5.2-positive donor cells were detected in the lungs of [3c mutant recipients 8 wk after transfer (Fig. 4 a) , whereas [3c to [3c (Ly 5.1) transplanted animal lung sections were negative for Ly5.2 staining (Fig. 4 b) . The morphology and the location of the engrafting Ly 5.2-positive cells suggested alveolar macrophage repopulation, a cell type known to repopulate after bone marrow transplant (8, 9) . Consistent with this finding was the reversal of the abnormal macrophage morphology that is characteristic for animals undergoing PAP. ilar to alveolar macrophages obtained from [3c mutant animals after transplantion with WT bone marrow (Fig. 4 d) , and in sharp contrast to those obtained from [3c mutant animals still undergoing PAP (Fig. 4 e) .
Given that transfer of WT bone marrow cells into [3c mutant mice reversed the course of the lung disease, transfer of ~c mutant bone marrow into WT animals may likewise be expected to cause the disease state. However, in four Table  1 . Bone marrow from WT or 13c mutant animals was transplanted into 13c mutant animals and 10 wk after transplantation total protein content of BAL fluid was determined from each group. Similar results were obtained when testing these samples by the Bradford protein determination method. mice evaluated 12 wk after transfer and in two mice evaluated 1 yr after transfer, we were unable to detect the PAPlike disease (Fig. 2) . The blood of these animals was repopulated by donor ]3c mutant cells, as evidenced by FACS | (Fig. 3 , BMT [3cKO-WT). The cyto-ablative treatment of the WT recipients by irradiation may not affect cell types such as terminally differentiated macrophages. These remaining radio-resistant cells in the WT animals may be sufficient to prevent the onset of the disease. Alternatively, since bone marrow replacement was not 100% (see Fig. 3 ), reseeding of the lung with WT precursor cells may be sufficient to prevent the disease.
Protein Accumulation in BAL Fluid
Group
RAG-2 Mutant Donor Bone Marrow
Reversed the PAP Disease. To begin to evaluate which cell type in the bone marrow reversed the disease state in the lung, we used RAG-2 mutant mice as the source of donor cells. As RAG-2 mutant animals do not contain lymphocytes (12) , the bone marrow from these animals are a source of donor cells more restricted to the myeloid lineage. Indeed, RAG-2 bone marrow was able to reverse the PAP disease in [3c recipient animals 12 wk after transfer (Fig. 2) . Animals showed no intraalveolar substance, identical to the findings of the WT (whole bone marrow) to 13c mutant animal transplantation.
The data presented in this report document that whole bone marrow from normal animals or bone marrow from RAG-2 mutant animals can effectively reverse 13c-deficient PAP. In previous work we had shown that grossly abnormal alveolar macrophage morphology was a characteristic of mouse 13c-deficient PAP (6) . This abnormal morphology was corrected after engraftment of donor-derived myeloid lineages into the lungs of [3c mutant animals after bone marrow tranplantation, whether or not the donor bone marrow contained the potential to develop lymphocytes. Taken together, these data indicate that a specialized alveolar macrophage dysfunction may cause this disease. A reasonable hypothesis would be a requirement o f G M -C S F stimulation of alveolar macrophages to effectively process and/or degrade pulmonary surfactant. Observations of abnormal alveolar macrophages have also been made in the human disease state (13, 14) . In support of this hypothesis, Huffrnan et al. (15) have recently described that transgenic expression of G M -C S F ligand by the lung tissue--specific SP-C promoter corrected PAP when bred to G M -C S F ligand-deficient mice.
In the studies reported here, we used ~c mutant recipient animals that were 2 -3 -m o old at the time of transfer, with the exception of the RAG-2 transplantation experiment where recipients were 7-too old. Considering that intraalveolar debris is present at 2 mo and more pronounced at 7 mo in the natural course of the disease, these studies indicate that bone marrow transplantation can not only prevent further progression of the disease, but also reverse a more established disease state. The ability of bone marrow to effectively reverse mouse PAP caused by loss of[3c expression is of significance to the human PAP disease state. A subset of severely affected pediatric PAP patients has been identified with a striking reduction or absence of 13c protein expression at the cell surface (Dirksen, U., R. Nishinakamura, P. Groneck, L. Nogee, R. Murray, and S. Burdach, manuscript submitted for publication). Thus, a subset of humans with this disease, where cells are unresponsive to GM-CSF by a cell-autonomous mutation, may be a candidate for bone marrow transplantation as a means of replacing the defective alveolar macrophage and reversing the disease process. Significantly, engraftment of donor bone marrow into human recipients has been shown by Thomas et al. (10) to result in donor-type alveolar macrophages when evaluated by lung biopsy samples.
The data presented here indicate that [3c-deficient mice will serve as a useful model of the PAP disorder, and also emphasize the utility of bone marrow transplantation to correct disease states that may not initially appear to be hematopoietic in nature.
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